Pharmaceutical composition for regulating PI3K-AKT signal channel of breast cancer cell and application of pharmaceutical composition
Through network pharmacology and molecular docking technology, the anti-breast cancer mechanism of licorice Zhongshan Kapoenol is clarified, and combined with cisplatin to form a pharmaceutical composition, solving the problem of major side effects and unclear mechanism of action of existing breast cancer treatment methods, realizing the More efficient breast cancer treatment effects and lower side effects.
Patent Information
- Application Number
- CN202410907677.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-15
AI Technical Summary
The existing breast cancer treatment methods have problems such as large side effects, limited therapeutic effects, and unclear mechanism of action on licorice active ingredients, especially how to accurately identify and isolate the most active and least side effects of breast cancer.
Through network pharmacological analysis and molecular docking technology, licorice Zhongshan kaempferol is clearly defined as the core active ingredient in anti-breast cancer, regulates the PI3K-AKT signaling pathway, and combines cisplatin as an active ingredient to enhance the therapeutic effect and reduce side effects, forming a pharmaceutical composition Used to inhibit breast cancer cell proliferation and induce cell apoptosis.
It is clarified that kaempol targets inhibition of PI3K-AKT signaling pathway by regulating the expression of genes such as PI3K, AKT, BAD, and BCL-2, providing a new mechanism of action and target for breast cancer treatment, improving the therapeutic effect and reducing the potential The toxic side effects have opened up the process of modernizing traditional Chinese medicine and provided new strategies for the treatment of breast cancer and other cancers.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the intersection of biomedicine and natural product drug development, specifically focusing on breast cancer treatment in oncology, and the application of natural drug chemistry and network pharmacology in drug development. This technology aims to develop new anti-tumor treatment strategies by exploring the inhibitory effect of kaempferol, an active ingredient in traditional Chinese medicine licorice, on breast cancer. Background Art
[0002] Currently, the treatment of breast cancer mainly includes surgical resection, chemotherapy and radiotherapy. However, these treatments may cause huge side effects and potential risks. Studies have shown that traditional Chinese medicine plays a significant role in the entire process of breast cancer treatment, not only affecting the recovery after breast cancer surgery, radiotherapy or chemotherapy, but also playing a role in the late and terminal stages of breast cancer.
[0003] Licorice (Glycyrrhiza uralensisFisch) is used as a harmonizing Chinese medicine in many traditional Chinese medicine prescriptions. Licorice contains more than 20 triterpenoids and nearly 300 flavonoids, among which glycyrrhizin, glycyrrhetinic acid, licochalcone A, licochalcone E, glabridin and liquiritigenin are important active ingredients. Since licorice has multi-target and multi-substance properties, it is challenging to explore its potential mechanism for treating diseases. Huang et al. found that licorice can inhibit the proliferation of A549 cells, a lung adenocarcinoma cell line, by inducing apoptosis. Isoliquiritigenin, as an active ingredient in licorice, mainly induces ferroptosis in gallbladder cancer by activating the p62-Keap1-Nrf2-HMOX1 signaling pathway and downregulating GPX4 expression. This phenomenon has been demonstrated in both in vivo and in vitro experiments. In addition, licorice can inhibit tumor cell proliferation and induce tumor cell apoptosis through a variety of strategies. Studies have shown that licorice can inhibit the proliferation of gastric cancer KATO III cells and induce DNA fragmentation into oligonucleotide fragments, suggesting that licorice may induce apoptosis in gastric cancer cells. In addition, licorice also reduces the expression of anti-apoptotic factor Bcl-2, increases the expression of pro-inflammatory factor Bax, and enhances the activity of caspase-9 and caspase-3, thereby inducing apoptosis of melanoma cells, thereby inhibiting tumor proliferation. In addition, studies have shown that licorice diprenylated flavonoids lupalbigenin and 6,8-diprenylated isoflavones (6,8-diprenylgenistein) induce SW480 colon cancer cell death by enhancing autophagy due to the presence of isopentenyl groups. In contemporary research, several studies have shown that licorice has potential therapeutic effects in the treatment of breast cancer. Licorice leaf extract can induce nuclear damage and apoptosis in breast cancer cells treated with urea, causing the cell cycle to arrest in the S phase, thereby inhibiting the proliferation of breast cancer. The reduction of MMP-2 / 9 expression induced by glycyrrhizic acid is obviously mediated by licorice's ability to specifically inhibit p38 MAPK activity and its activation of downstream AP1. At the same time, licorice inhibits the invasion of highly metastatic breast cancer cells by affecting the p38MAPK-AP1 signaling pathway. Although research on the mechanism of licorice in treating breast cancer has emerged, due to the characteristics of licorice's multiple active ingredients and multiple action targets, its anti-breast cancer mechanism has never been systematically and comprehensively understood.
[0004] With the development of technology, in the past decade, various technologies such as genomics, transcriptomics, and proteomics have been widely used in high-throughput screening and identification of targets involved in traditional Chinese medicine formulas. However, the use of these technologies is relatively expensive and requires complex analysis procedures. Based on this, network pharmacology came into being. By combining pharmacology, bioinformatics and other sciences, a network related to "disease-phenotype-gene-drug" is constructed to systematically explain the multi-component, multi-target drug treatment mechanism from the perspective of gene distribution, molecular function and signal pathways. This convenient and comprehensive research method provides an important way to study the mechanism of traditional Chinese medicine.
[0005] Although the research on licorice and its active ingredients in the field of breast cancer treatment has achieved initial results, there are still several key issues that limit its clinical transformation and wide application: including 1. Unclear mechanism of action: Although licorice is known to inhibit tumor cell proliferation and induce apoptosis through multiple mechanisms, its multi-active ingredients and multi-target characteristics make the overall mechanism of action complex and unclear, especially the specific action pathways and molecular mechanisms for breast cancer. There is still a lack of systematic and in-depth understanding. 2. Accurate identification and separation of active ingredients: Licorice contains a large number of different chemical components. How to accurately identify and separate the most active and least side-effect active ingredients for breast cancer from these components is a key problem in achieving precision treatment. 3. Dose and ratio optimization: Existing research lacks sufficient data support for the optimal dosage and ratio of licorice active ingredients and the optimal strategy for combined use with other treatment methods, which is crucial to maximizing treatment effects and reducing side effects.
[0006] In summary, future research needs to focus on clarifying the molecular mechanism of licorice's anti-breast cancer effect, optimizing the extraction and application strategy of active ingredients, strengthening clinical research evidence, and solving standardization and economic issues, so as to promote substantial progress in the treatment of breast cancer using licorice and its active ingredients. Summary of the invention
[0007] The present invention aims to solve the limitations of existing treatment methods in the field of breast cancer treatment, such as the limitations of treatment effects, the burden of side effects borne by patients, and the lack of understanding of specific bioactive ingredients and their mechanisms of action. Specifically, although traditional Chinese medicine and its bioactive ingredients have shown potential in cancer treatment due to multiple targets, significant pharmacological effects and fewer side effects, how to identify the effective ingredients and mechanisms of action from complex traditional Chinese medicine components, especially how to improve the bioavailability and targeted therapeutic effects of these ingredients, is still a key technical challenge that needs to be solved. This study focuses on clarifying the core active ingredient of licorice against breast cancer, kaempferol, and its specific mechanism of action in inhibiting the development of breast cancer by regulating the PI3K-AKT signaling pathway, aiming to overcome the above difficulties. Through network pharmacology analysis, molecular docking technology, and in vitro and in vivo experimental verification, the present invention successfully identified and verified kaempferol in licorice extract as the core active ingredient against breast cancer; finding drugs that produce synergistic effects with it for combined treatment can effectively inhibit the proliferation of breast cancer cells and induce cell apoptosis.
[0008] First, the present invention provides a pharmaceutical composition for regulating the PI3K-AKT signaling pathway of breast cancer cells, wherein the composition comprises kaempferol as a main active ingredient.
[0009] For the technical solution described above, it is further preferred that at least one pharmaceutically acceptable carrier or adjuvant is further included, such as a carrier, a diluent, a stabilizer or a preservative, for improving the physical stability of the drug and patient compliance.
[0010] For the technical solution described above, it is further preferred that the composition is used to inhibit breast cancer cell proliferation and induce cell apoptosis by affecting the expression of genes such as PI3K, AKT, BAD and BCL-2, thereby treating or preventing breast cancer.
[0011] For the technical solution described above, it is further preferred that licorice extract is included as an auxiliary active ingredient. Kaempferol and other flavonoids contained in the licorice extract act together on breast cancer treatment to improve the treatment effect by regulating signal pathways.
[0012] For the technical solution described above, it is further preferred that the composition comprises kaempferol and cisplatin as active ingredients to enhance the therapeutic effect, reduce the side effects of monotherapy, and improve the patient's prognosis. The composition is particularly suitable for treating breast cancer types that are resistant to traditional chemotherapy drugs.
[0013] In an embodiment of the present invention, the dosing regimen for the mouse model is set in detail. Specifically, the dosage of kaempferol given to mice by oral gavage is set to 100 milligrams per kilogram per day (100mg / kg / d), and the bioavailability under this approach is evaluated to be 20% (i.e. 0.2). Relatively, if the drug is administered by intraperitoneal injection, the bioavailability of this approach reaches 100% (1.0). In order to ensure that the same effective drug concentration is achieved in the body under the two modes of administration, we convert the dosage according to the bioavailability. The specific calculation method is as follows: the target dose of oral gavage needs to be multiplied by the bioavailability factor by the original dose, that is, 50 to 200 milligrams per kilogram (50-200mg / kg) multiplied by 0.2, and the target dose of intraperitoneal injection should be 10 to 40 milligrams per kilogram (10-40mg / kg). Therefore, when it is planned to administer kaempferol to mice by intraperitoneal injection, the recommended dosage range is 10 to 40 milligrams per kilogram.
[0014] Considering the conversion of drugs from animal experiments to human applications, refer to the following formula:
[0015] HED(mg / kg)=Animal NOAEL(mg / kg)*(Weight animal(kg) / Weight human(kg))^(1-0.67)
[0016] Human weight = 60kg
[0017] Mice weight = 0.02 kg
[0018] Animal NOAEL(mg / kg)10-40mg / kg / d
[0019] NOAEL is the dose at which no adverse effects are observed;
[0020] The corresponding dosing concentration of kaempferol in humans can be further estimated. Based on the above intraperitoneal injection dose range for mice, the dose range converted to humans is 0.81-3.24 mg / kg / d, aiming to achieve similar therapeutic effects and safety considerations as in mouse experiments.
[0021] Mouse human body Kaempferol 10–40 mg / kg / day 0.71–2.85 mg / kg / day Cisplatin 0.5-2 mg / kg / 2 days 0.036-0.14 mg / kg / day
[0022] The ratio of kaempferol to cisplatin in mice is (5-80): 1; kaempferol 10-40 mg / kg / d; cisplatin 0.5-2 mg / kg / d. In the most preferred case, the dosage of kaempferol and cisplatin in the composition of the embodiment is 20 mg / kg / d and 1 mg / kg / d respectively.
[0023] According to the experimental data in the following text, the ratio of kaempferol to cisplatin in the human body is (5-79):1; kaempferol 0.71-2.85 mg / kg / d, cisplatin 0.036-0.14 mg / kg / d. In the most preferred case, the dosage of kaempferol and cisplatin in the composition of the embodiment is 1.62 mg / kg / d and 0.081 mg / kg / d respectively.
[0024] When the composition is used in mammals (including mice and humans), the ratio of kaempferol to cisplatin in the composition is (5-80):1; wherein, kaempferol is 0.71-40 mg / kg / d, and cisplatin is 0.036-2 mg / kg / d; the ratio of kaempferol to cisplatin is preferably (18-22):1, and the most preferred ratio of kaempferol to cisplatin is 20:1.
[0025] For the technical solution described above, it is further preferred that the composition is in the form of an oral preparation, an injection, a sustained-release preparation or a targeted delivery system to optimize the bioavailability and therapeutic effect of the drug to adapt to different treatment needs and patient preferences.
[0026] Another aspect of the present invention is to provide a pharmaceutical use of the composition, which relates to the preparation of a drug for inhibiting the proliferation or metastasis of breast cancer cells in mammals (especially humans). The anti-breast cancer effect is exerted by regulating the activity of the PI3K-AKT signaling pathway in mammals, especially inhibiting the expression of AKT and Bcl2 proteins, so as to inhibit the development of breast cancer, reduce the viability of breast cancer cells, and promote cell apoptosis.
[0027] For the technical solution described above, it is further preferred that, in the use, the pharmaceutical composition is in the form of an oral preparation, an injection, a sustained-release preparation or a targeted delivery system. The pharmaceutical composition is designed to enhance the therapeutic effect and reduce side effects through a specific administration regimen, such as periodic administration or combined with an existing breast cancer treatment regimen.
[0028] Beneficial effects of the present invention:
[0029] It was clarified that kaempferol regulates the expression of key genes such as PI3K, AKT, BAD, and BCL-2, and targets the PI3K-AKT signaling pathway, providing a new mechanism of action and target for the treatment of breast cancer.
[0030] It has improved the scientific understanding of the mechanism of licorice's anti-breast cancer effect and provided a strong theoretical and experimental basis for the treatment of breast cancer based on traditional Chinese medicine.
[0031] By optimizing the administration method and formulation of kaempferol, the bioavailability is improved, the therapeutic effect of kaempferol as an anti-breast cancer drug is enhanced, and the potential toxic side effects are reduced.
[0032] It has opened up a new path combining modern network pharmacology with traditional Chinese medicine research, promoted the modernization and internationalization of Chinese medicine, and provided new strategies for the treatment of breast cancer and other cancers. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 Experimental flow chart of the present invention;
[0034] Figure 2 Venn diagram of breast cancer disease targets;
[0035] Figure 3 Venn diagram of drug-disease intersection targets;
[0036] Figure 4 Protein interaction network diagram of licorice in treating breast cancer;
[0037] Figure 5 Network diagram of active ingredients and targets of licorice in the treatment of breast cancer;
[0038] Figure 6 GO enrichment analysis of the core targets of licorice in treating breast cancer;
[0039] Figure 7 KEGG enrichment pathway analysis results of licorice core targets in the treatment of breast cancer;
[0040] Figure 8 Target-pathway network diagram of licorice in treating breast cancer;
[0041] Fig. 9 Molecular docking diagram of kaempferol and its target;
[0042] Fig.10 Effects of kaempferol on proliferation of MDA-MB-231 cells;
[0043] Fig.11 Kaempferol inhibits the activation of PI3K-AKT pathway in MDA-MB-231 cells. *p<0.05, **p<0.01, ***p<0.001;
[0044] Fig.12 Effect of kaempferol on the migration ability of MDA-MB-231 cells (magnification 40x). *p<0.05, **p<0.01;
[0045] Fig.13 Kaempferol inhibits the proliferation of breast cancer cells in mice *p<0.05;
[0046] Fig.14 The morphology of mouse mammary gland and mammary tumor in situ;
[0047] Fig.15 RT-qPCR results of PI3K-AKT pathway-related genes in mouse tumor tissues; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001;
[0048] Fig.16 Immunohistochemistry showed that kaempferol inhibited the expression of AKT and Bcl2 in vivo, ****p<0.0001. DETAILED DESCRIPTION
[0049] It should be understood that the specific embodiments described below are only examples of the present invention and are not intended to limit the scope of protection of the present invention. Any person familiar with the art can make various adjustments and changes based on the core teachings of the present invention, which are deemed to fall within the scope of protection of the present invention.
[0050] Figure 1 It is an experimental flow chart of the present invention;
[0051] In this study, the pharmacological network of licorice in breast cancer was constructed using network pharmacology methods, aiming to predict its active ingredients, potential protein targets and related pathways. And biological experiments were used to verify in vivo and in vitro experiments. Network pharmacology analysis revealed that kaempferol, as the core active ingredient of licorice against breast cancer, inhibited the activity of breast cancer cells by regulating the expression of genes such as PI3K, AKT, BAD, and BCL-2 in the PI3K-AKT pathway. At the same time, in vivo and in vitro experiments verified that kaempferol, the core ingredient of licorice, has a significant anti-breast cancer effect and interferes with the expression of genes related to the PI3K-AKT pathway in breast cancer cells. It was verified in two dimensions of bioinformatics and biological experiments: licorice inhibits the development of breast cancer by regulating the PI3K-AKT signaling pathway of breast cancer cells. This study applied network pharmacology methods and experiments to construct a reliable system network to predict and verify the main bioactive ingredients, potential targets and molecular mechanisms of licorice in breast cancer. In addition, it provides a new way to clarify the potential mechanism of breast cancer treatment and reveals the value of licorice in treating breast cancer.
[0052] Based on the ADME criteria, 94 active licorice compounds were screened from the TCMSP database, and then 1,368 all disease targets were obtained from the TTD, DrugBank, pharmagGKB, and GeneCard databases, and a total of 63 putative licorice anti-breast cancer targets were identified. Through the analysis of the drug component-target network, five anti-human breast cancer active ingredients of licorice (quercetin, kaempferol, licorice chalcone A, naringenin, and flavonoids) can be obtained. These five compounds are all flavonoids, which belong to various flavonoids of traditional Chinese medicine and have been shown to have anti-tumor activity. As a natural compound, kaempferol has been studied a lot in the field of cancer treatment and prevention. Its anticancer mechanism may include growth inhibition, induction of apoptosis, and inhibition of breast cancer cell migration. However, according to pharmacokinetic studies, these five active ingredients have the characteristics of low bioavailability and poor water solubility. Pharmacokinetic studies have shown that high-polarity glycosides such as kaempferol are poorly absorbed. After oral administration, kaempferol is present in the blood at nanomolar concentrations only, and kaempferol glycosides are metabolized into glycoside compounds by intestinal enzymes in the small intestine and colonic flora, which are then converted and absorbed into the circulation system. At present, the application of active ingredients of traditional Chinese medicine in preparations has certain limitations, and further pharmacokinetic studies are needed to solve the problem of low bioavailability of traditional Chinese medicine ingredients.
[0053] GO functional analysis showed that many molecular functions, including response to transcription factor binding, nuclear receptor activity, chormatin binding, and transcription initiation factor binding, were associated with the effects of licorice in breast cancer. Damage to breast cancer cells is associated with inhibition of cell growth by inhibiting the cell cycle. The targets of this study were enriched in immune-related PI3K-AKT, p53 signaling pathways, and cancer pathways. Previous studies have shown that the PI3K / AKT / mTOR pathway is frequently activated in cancer, leading to increased cell proliferation, survival, and metabolism. Dysregulation of PI3K signaling may occur through mutations in PIK3CA, loss of PTEN, or activation of upstream receptors such as HER2. TP53 is a tumor suppressor gene that is commonly mutated in cancer. Loss of p53 function can lead to uncontrolled cell growth, genomic instability, and resistance to therapy. Cell cycle arrest, DNA repair, apoptosis, and senescence are regulated by the p53 pathway to respond to cellular stress.
[0054] Finally, molecular docking was used to evaluate the spatial binding of seven key target proteins (AKT1, AKT3, PI3K, TP53, EGFR, INSR and CDK4) of licorice that affect breast cancer cell function through the PI3K-AKT pathway and the core active ingredient, kaempferol. The binding affinity of the docking results was in the range of -6.5 to -10.1 kcal / mol, indicating that all targets had good docking ability with kaempferol. This article shows that the core active ingredient has the potential to achieve a therapeutic effect on breast cancer by directly intervening in the above targets. However, in order to confirm the accuracy of the prediction results, it is still necessary to conduct in vitro and in vivo experiments.
[0055] In order to further verify the targeting effect of kaempferol on key cancer genes, the RT-qPCR method was used to evaluate whether the PI3K-AKT pathway of MDA-MB-231 breast cancer cells was regulated under kaempferol treatment. The results showed that the mRNA expression of PI3K, AKT and BCL2 in breast cancer cells in the kaempferol group was significantly decreased compared with that in the control group. Previous studies have shown that kaempferol can induce apoptosis of cancer cells through various mechanisms, including activation of caspase, disruption of mitochondrial function and regulation of Bcl-2 family proteins. However, molecular docking results showed that kaempferol could not directly bind to BCL2 protein. Therefore, targeting PI3K and AKT to regulate BCL2 expression is an effective therapeutic strategy for breast cancer.
[0056] The effect of kaempferol on breast cancer in vivo was investigated by establishing a mouse 4T1 breast cancer orthotopic tumor model. The results showed that after kaempferol was administered to mice in vivo, the morphology of breast tumor tissue was destroyed. Similar to the in vitro experiments, the expression of Akt and Bcl2 in breast cancer cells was inhibited after kaempferol treatment. These results support the network pharmacology data, proving that kaempferol exerts its anti-breast cancer effect by affecting the activation of core genes in the PI3K-AKT signaling pathway.
[0057] In summary, combined with network pharmacology prediction and experimental verification, the pharmacological mechanism of licorice in treating breast cancer was determined. It is clear that the core active ingredient of licorice in treating breast cancer is kaempferol, and the core targets include PI3K, AKT, BAD and BCL-2. By reducing the expression of AKT and BCL-2 in breast cancer cells, accompanied by the accumulation of reactive oxygen species (ROS), the integrity of mitochondria is damaged, leading to changes in mitochondrial membrane potential, inducing apoptosis pathways, and destroying the normal function of breast cancer cells, so as to achieve the effect of treating breast cancer. This study still has some defects that need to be improved, including the need for in-depth research on bioactive ingredients. At the same time, transcriptomics, proteomics, CRISPR-Cas9 and other technologies can be used to comprehensively and accurately analyze the mechanism of action of licorice in treating breast cancer. Based on network pharmacology and experimental verification, this study confirmed the feasibility of licorice in treating breast cancer, and preliminarily explored its mechanism of action, providing new theoretical support for the development of new anticancer drugs.
[0058] All statistical data were analyzed using GraphPad Prism software (version 10.0, GraphPad Software, Inc., LaJolla, CA, USA). Image results were quantitatively analyzed using ImageJ software. All experiments were repeated at least 3 times independently, and the experimental data were presented as mean standard deviation. The t-test was used for comparison between the two groups, and one-way analysis of variance (ANOVA) was used for statistical analysis between multiple groups. The p values shown in each figure, including *p<0.05, **p<0.01, **p<0.001, ***p<0.0001, ****p<0.00001, were all significant.
[0059] Example 1
[0060] 1. Screening of effective ingredients and prediction of action targets of licorice
[0061] All known related components of licorice were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) for ADME screening. The screening conditions were set as oral bioavailability (OB) ≥ 30% and drug like (DL) ≥ 0.18. At the same time, the targets of each active ingredient of licorice were collected, and the protein target information was standardized in the Uniprot database (https: / / www.uniprot.org / ). The active ingredients and targets of licorice were obtained. As a result, the chemical components of licorice were obtained in the TCMSP database. After screening, 94 active ingredients were obtained. The targets of each active ingredient were retrieved in the TCMSP database, and 211 targets were obtained by importing the Uniprot database for gene standardization.
[0062] 2. Screening of disease targets in human breast cancer
[0063] Using "Breast Cancer" as the keyword, we searched: ① DrugBank database ( https: / / go.drugbank.com / ②PharmGKB database ( https: / / www.pharmgkb.org / )③GeneCards database( https: / / www.genecards.org )④Therapeutic Target Database (TTD, https: / / db.idrblab.net / ttd / ) Four databases were used to search for breast cancer disease-related targets respectively, and the results were integrated to obtain human breast cancer disease targets.
[0064] Results, such as Figure 2 As shown, breast cancer disease targets were retrieved through TTD database, DrugBank database, pharmGKB database and GeneCards database, and a total of 1568 breast cancer disease-related targets were obtained. After deleting duplicate targets, a total of 1368 breast cancer disease targets were obtained.
[0065] 3 Target screening of licorice in the treatment of breast cancer
[0066] The jvenn (https: / / jvenn.toulouse.inrae.fr / app / example.html) online tool was used to intersect the licorice active ingredient targets and human breast cancer disease targets to obtain the potential targets of licorice for the treatment of breast cancer.
[0067] As a result, the disease targets and licorice active ingredient targets were intersected and a Venn diagram was drawn, and finally 63 licorice-related targets for breast cancer treatment were obtained. Figure 3 .
[0068] 4 Construction of drug-disease target PPI network
[0069] The intersection targets were imported into the STRING database (https: / / cn.string-db.org / ), and the screening conditions were set to "Homo sapiens, confidence>0.7, and the protein interaction network was analyzed. The results were imported into cytoscape3.9.0 software for visualization analysis, and the drug-disease key targets were obtained based on the degree calculation. At the same time, cytoscape3.9.0 was used to construct the PPI network diagram.
[0070] Results of PPI network and core gene screening of licorice in treating breast cancer: The intersection targets were imported into the String database to obtain the protein interaction network (PPI) and corresponding network data. The network has 61 nodes and 1185 edges. The target association degree (degree) was calculated and analyzed using the NetworkAnalyzer in Cytoscape3.9.0. Among them, TP53 is the most core target, and the related action network was extracted to obtain the core PPI action network of each target of licorice in treating breast cancer. Figure 4 .
[0071] 5 Prediction of effective components and key targets of licorice in treating breast cancer
[0072] The "drug-target" network diagram was drawn using Cytoscape 3.9.0 software, and the degree of association was calculated using the built-in tool Network Analyzer to screen out the main active compounds and gene targets of licorice.
[0073] Results: Based on the interaction between the active ingredients in licorice and the disease targets of breast cancer, the interaction network diagram of licorice active ingredients-disease target genes was constructed, and 63 possible targets of licorice in the treatment of breast cancer were obtained. The active ingredient-target network pathway diagram was visualized and analyzed using Cytoscape 3.9.0 software. There are 109 nodes and 534 edges in the network diagram. The lines between the nodes represent the interaction between the active ingredients and the disease targets, and the active ingredients and targets are analyzed according to the degree value. The top five targets and active ingredients include: quercetin, kaempferol, licochalcone a, naringenin and formononetin. For details, see Figure 5, Table 1.
[0074] Table 1 Core active ingredients and targets of licorice in treating breast cancer
[0075] MOLID MoleculeName Degree Target Degree MOL000098 quercetin 24 AR 66 MOL000422 kaempferol 14 GSK3B 56 MOL000497 licochalconea 8 CDK2 56 MOL004328 naringenin 6 PTGS1 41 MOL000392 formononetin 5 PPARG 4
[0076] 6.GO function and KEGG pathway enrichment analysis
[0077] The key targets screened were imported into the Metascape database for Gene Ontology (GO) analysis and Kyoto encyclopedia of genes and genomes (KEGG) signal pathway enrichment analysis. GO analysis was explored from three perspectives: molecular function (MF), biological processes (BP), and cellular component (CC). The species was set to "H.sapiens", the enrichment conditions were Min Overlap to 3, p Value Cutoff to 0.05, MinEnrichment to 1.5, and all analysis files were downloaded. The data was imported into the Micro-Informatics (https: / / www.bioinformatics.com.cn / ) biological analysis online platform to draw GO and KEGG enrichment biological function analysis and visualization diagrams.
[0078] As a result, the 63 potential target genes of licorice in treating breast cancer were imported into Metascape for gene ontology (GO) enrichment analysis, including molecular function, biological process and cell components. The screening conditions were Min Overlap of 3, PValue Cutoff of 0.05 and Min Enrichment of 1.5, indicating that the biological function was significant.
[0079] The GO enrichment results of key targets showed that the molecular functions mainly involved polymerase II-specific DNA-binding transcription factor binding (GO:0061629:RNA polymerase II-specific DNA-binding transcriptionfactorbinding), DNA-binding transcription factor binding (GO:0140297:DNA-binding transcriptionfactor binding), transcription factor binding (GO:0008134:transcription factor binding), nuclear receptor activity (GO:0004879:nuclear receptor activity), ligand-activated transcription factor activity (GO:0098531:ligand-activatedtranscription factor activity), etc.
[0080] The key targets were significantly enriched in biological processes such as response to exogenous stimuli (GO:0009410:response toxenobiotic stimulus), cellular response to exogenous stimuli (GO:0071466:cellular response toxenobiotic stimulus), xenobiotic metabolic process (GO:0006805:xenobiotic metabolic process), regulation of hormone levels (GO:0010817:regulation of hormone levels), and secondary metabolic process (GO:0019748:secondary metabolic process).
[0081] At the cellular component level, it includes transcription regulator complex (GO:0005667:transcriptionregulator complex), RNA polymerase II transcription regulator complex (GO:0090575:RNApolymerase IItranscription regulator complex), membrane raft (GO:0045121:membrane raft), membrane microdomain (GO:0098857:membrane microdomain) and cave (GO:0005901:caveola). Figure 6 .
[0082] Results: According to the KEGG analysis results of the intersection targets, 146 pathways were screened (p<0.05), and it was found that cancer pathway (hsa05200: Pathways in cancer), hepatitis C (hsa05160: Hepatitis C), measles (hsa05162: Measles), Epstein-Barr virus infection (hsa05169: Epstein-Barr virus infection), prostate cancer (hsa05215: Prostate cancer), p53 signaling pathway (hsa04115: p53 signaling pathway), PI3K-Akt signaling pathway (hsa04151: PI3K-Akt signaling pathway), small cell lung cancer (hsa05222: Small cell lung cancer), endocrine resistance (hsa01522: Endocrine resistance) and Kaposi sarcoma-associated herpesvirus infection (hsa05167: Kaposi sarcoma-associated herpesvirus infection) were the top ten significant pathways. The PI3K-AKT pathway plays a key role in regulating the biological behavior of cancer cells, affecting cell proliferation, cell cycle, inducing apoptosis and DNA repair, etc. These results suggest that licorice may participate in the anti-breast cancer effect through the PI3K-AKT signaling pathway. Figure 7 .
[0083] Construction of target-pathway network;
[0084] In order to more accurately illustrate the possible mechanism of action of licorice in treating breast cancer, the first 10 pathways and their targets were selected to obtain a target-pathway network diagram with 50 nodes and 304 action associations. Figure 7 It can be seen that cancer pathway, hepatitis C, PI3K-AKT pathway, measles, Epstein-Barr virus infection, TP53, CCND1, CDK4, CASP9, CDK2, BCL2, BAX, RB1, NFKBIA and CASP3 are the core regulatory nodes of the network. Combined with the above, it is suggested that licorice may effectively induce apoptosis of breast cancer cells by regulating the PI3K-AKT pathway, thereby achieving the purpose of treating breast cancer. Figure 8 .
[0085] 7. Molecular Docking
[0086] The potential core small molecules found in the previous search were downloaded from the PubChem database in mol2 format and converted into sdf format files using Pymol 2.5.4 software. The files were imported into AutoDock Tool 4 software to remove water and add hydrogen, and the results were saved as pdbqt format files. The PDB format files of the acceptors were queried in the Crystalline Protein Structure Database (https: / / www.rcsb.org / ), and the bound water was removed and the atomic charges were added using AutoDock Tool4 software, and the results were saved as pdbqt format files.
[0087] Molecular docking experiments were performed in batches using AutoDockVina software, and the docking results were evaluated based on their binding energy and binding sites and visualized using Pymol 2.5.4 software.
[0088] Results: According to the active ingredient-target network diagram of licorice for the treatment of breast cancer and the target-pathway network diagram of licorice for the treatment of breast cancer, the active ingredients, targets and pathways of licorice were obtained respectively. Based on literature research, it has been reported that kaempferol has the potential to treat other cancers, but the research on breast cancer is still insufficient. Combined with the above results, licorice may achieve the purpose of treating breast cancer by regulating the PI3K-AKT pathway. Based on this, kaempferol (MOL000422) was selected as a ligand, and the targets of the PI3K-AKT pathway and the core targets of the pathway, PI3K, AKT1, AKT2, TP53, EGFR, INST, and CDK4, were enriched as receptors for molecular docking. The molecular docking results are shown in Fig. 9 .
[0089] Example 2 In vivo and in vitro experimental verification of the anti-breast cancer effect of kaempferol and its mechanism
[0090] Experimental materials
[0091] Human breast cancer MDA-MB-231 and mouse breast cancer 4T1 were donated by RSBM public welfare cell bank (http: / / biotechrs.cn / ).
[0092] Thirty SPF balb / c female mice, 4-6 weeks old, weighing 18-20 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. (Quality Certificate No.: 110011244402292142, License No.: SCXK(Beijing)20160006). The animals were uniformly raised in the Experimental Animal Center of Shenyang Agricultural University. The treatment of mice during the experiment complied with animal ethical standards.
[0093] Cisplatin (CAS No.: 520-18-3) and kaempferol (CAS No.: 15663-27-1) were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0094] Table 2 Sources of biochemical reagents
[0095] Reagent name Manufacturer Picric acid saturated aqueous solution Yuanmu Biology Ethanol Sangon Biotech HE dye solution Aladdin Protein Extraction Kit KeyGene Biotechnology Trizol ThermoFisher, USA Chloroform Sinopharm Chemical Reagent Co., Ltd. RPMI1640 medium HyClone FBS (Fetal Bovine Serum) Israeli BI Company MTT (Thiazolyl Blue) Solarbio Technology Co., Ltd. 0.4% Trypan blue dye Solarbio Technology Co., Ltd. Trypsin HyClone Penicillin-Streptomycin Mixture HyClone DMSO (Dimethyl Sulfoxide) Solarbio Technology Co., Ltd. PBS (Phosphate Buffered Saline) HyClone BetaActinRabbit Proteintech mouseanti-AKT CellSignalingTechnology Cisplatin Aladdin Kaempferol Aladdin rabbitanti-Bcl2 CellSignalingTechnology
[0096] Table 3 Experimental instruments
[0097]
[0098]
[0099] Cell culture
[0100] Take out the MDA-MB-231 human breast cancer cells and 4T1 mouse breast cancer cells frozen in liquid nitrogen, thaw in a 37°C water bath for 1-2 minutes, quickly transfer the cell suspension into 10 times the volume of serum-free 1640 culture medium, centrifuge for 3 minutes, discard the supernatant, add 1640 culture medium (89% 1640 + 10% FBS + 1% penicillin and streptomycin), and place in a cell culture incubator for culture. When the cells grow to about 80% of the bottom area of the dish, perform cell passage. Discard the original culture medium in the dish, add 2ml PBS solution to wash twice, then add 1ml 0.25% trypsin to digest, add 1640 culture medium to terminate digestion, centrifuge for 3 minutes, discard the supernatant and add culture medium, distribute to 2-3 new culture dishes for continued culture, and freeze the cells when the cell quantity is sufficient.
[0101] Experimental Animal Husbandry
[0102] Thirty balb / c female mice (4-6 weeks old, 18-20 g) required for the experiment were purchased from Beijing Weitong Lihua Company. The feeding and experimental operations of mice were carried out in the SPF barrier environment of the Experimental Animal Center of Shenyang Agricultural University. They were given sufficient sterile food and water, and the temperature (23-26°C) and humidity (40-50%) of the breeding environment were kept at the most suitable temperature. Sterile bedding was replaced regularly to maintain a 12 / 12 circadian rhythm. The experimental animal process complied with the principles of animal welfare, and the cervical dislocation method was used to kill the animals at the end of the experiment.
[0103] Drug configuration and dosage
[0104] Weigh 0.002 g of kaempferol using an analytical balance, add 200 μl of DMSO to completely dissolve the kaempferol to obtain a kaempferol stock solution, and store it at -20°C in the dark. When using, add complete culture medium to dilute it so that the final concentration of DMSO is 1‰.
[0105] 1. MTT assay to detect the effect of drugs on cell proliferation
[0106] Take the MDA-MB-231 cells in the logarithmic growth phase, digest them, centrifuge them, and resuspend them to prepare a single cell suspension. The cell density was adjusted to 50,000 cells / ml. 100 μl of cell suspension was added to each well of the 96-well plate. After 12 hours, the cells adhered to the wall. According to the experimental design, 10 concentration gradients of 0, 10, 20, 40, 80, and 90 mg / L were set, with 6 replicate wells in each group, and 3 blank wells (only culture medium) and 3 positive control wells (10 μmol / L cisplatin) were set, and incubated in the incubator for 24 hours and 48 hours. 20 μL of MTT (5 mg / mL) was added to each well. After incubation in the dark for 4 hours, the liquid in the well was discarded, 150 μL of DMSO was added to each well, and the well was shaken in the dark for 10 minutes. The absorbance at 490 nm was measured by an enzyme marker. Calculate the cell proliferation rate: The experiment was repeated 3 times.
[0107] The MTT method was used to investigate the effect of kaempferol on the proliferation of MDA-MB-231 cells, and the inhibition rate of cells after 24h and 48h of intervention with different concentrations of kaempferol was detected. Fig. 9 It can be seen that compared with the blank group, there was no statistical difference in the inhibition rate of cell proliferation under the treatment of 0-40mg / L kaempferol concentration, and the inhibition ability was poor; compared with the blank group, kaempferol had statistical significance under the treatment of 80mg / L and 90mg / L concentrations (p<0.05); and the results showed that the inhibition rate of kaempferol on MDA-MB-231 cell proliferation gradually increased with the increase of concentration and the passage of time. Fig.10 , *p<0.05, **p<0.01.
[0108] 2. RT-qPCR detection of related gene expression levels in breast cancer cells and tissues
[0109] Total RNA was extracted from cells and tumor tissues using an RNA extraction kit and cDNA was synthesized. Amplification was performed using the RT-qPCR kit, and the melting curve was analyzed after completion to determine whether there was nonspecific amplification. The amplification curve was analyzed and the Ct value was calculated. β-actin was used as an internal reference. -△△Ct The difference of mRNA expression level among the groups was calculated by PCR, and the experiment was repeated 3 times. The primer sequences are shown in Table 4.
[0110] Table 4 Real-time fluorescence quantitative PCR primer sequences
[0111] Gene name Forward sequence Reverse sequence hu-β-actin TTCTACAATGAGCTGCGTGTG GGGGTGTTGAAGGTCTCAAA hu-PI3K CCACGACCATCATCAGGTGAA CCTCACGGAGGCATTCTAAAGT hu-AKT1 CTACCCACACAGCAGTACGC AAGTCGCTGGTGTTAAGCCG hu-AKT2 AGGCACGGGCTAAAGTGAC CTGTGTGAGCGACTTCATCCT hu-AKT3 AATGGACAGAAGCTATCCAGGC TGATGGGTTGTAGAGGCATCC hu-BAD GCTGCACGATCTGGGAACC CTCCACAGTACACCACGTTG hu-BCL-2 TGGTCGCCTTCGGATGTTG CCTGTCTGTCCCTTAATGGTTTC mu-β-actin AAACTATGTCGGACGGCCAAA TGCTTTCGGTCCAATGAACAG mu-PI3K CGAGAGTGTCGTCACAGTGTC TGTTCGCTTCCACAAACACAG mu-AKT1 CTGCTCCTAGTCCACCACCT AGAGACCTCCATTATCGCTACC mu-AKT2 ACGTGGTGAATACATCAAGACC GGGCCTCTCCTTATACCCAAT mu-AKT3 AGGTTGGGTTCAGAAGAGGG AGGGGATAAGGTAAGTCCACATC mu-BAD GCAGCGGTGTGTTCTAGGTC TGCCATTGGATTTCCCATGTT mu-BCL-2 ACGTGGACCTCATGGAGTG TGTGTATAGCAATCCCAGGCA
[0112] Total mRNA was extracted from mouse tumor tissues and RT-qPCR was used to detect the expression levels of PI3K-AKT pathway marker genes. Compared with the control group, the expression levels of Pi3k and Bcl2 mRNA in each treatment group were increased, and the expression levels of Akt and Bcl2 were significantly decreased. This indicates that kaempferol may inhibit Akt expression in mice by overactivating Pi3k. By activating the downstream pro-apoptotic factor Bad, the apoptosis pathway is activated and the growth factor Bcl2 is inhibited, thereby inhibiting tumor growth. However, although the tumor volume in the combination group was the lowest among all groups, the expression of Bcl2 was significantly increased under the action of the drug, indicating that it may be regulated by other pathways at the same time. The difference was statistically significant. Figure 15 RT-qPCR results of PI3K-AKT pathway-related genes in mouse tumor tissues. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0113] Kaempferol inhibits PI3K / AKT pathway activation in breast cancer cells
[0114] Based on the above network pharmacology prediction, licorice may inhibit the PI3K-AKT pathway and mediate the activation of the downstream apoptosis pathway, thereby achieving the effect of treating breast cancer. Kaempferol is the core potential effective ingredient of licorice in treating breast cancer. In order to verify the molecular mechanism of kaempferol in treating sensitive breast cancer, MDA-MB-231 breast cancer cells were treated with appropriate concentrations of kaempferol for 24 hours, and then RT-qPCR was used to detect the expression changes of PI3K, AKT1, AKT2, AKT3, BAD and Bcl2. The results showed that kaempferol may inhibit the decrease of the total expression of downstream AKT by reducing the expression of PI3K, thereby activating the increase of the expression of downstream pro-apoptotic factor BAD and inhibiting the expression of growth factors.
[0115] Since Bcl2 is a key anti-apoptotic protein, it mainly activates the mitochondrial outer membrane channel and causes cell apoptosis by regulating mitochondrial permeability and cell membrane receptor expression. Based on this, Mito-Tracker Red CMXRos dye was used for mitochondrial labeling. Under a laser confocal microscope, it can be observed that the mitochondrial membrane potential of these cells is activated. At the same time, due to the increase in the phosphorylation level of AKT, the expression of downstream NADPH oxidase will increase, thereby accumulating reactive oxygen species (ROS) and damaging the cell membrane. DCFH-DA dye was used to detect the changes in the accumulation of cellular ROS under kaempferol treatment. It was found that under kaempferol treatment, the accumulation of cellular ROS increased.
[0116] Therefore, the activation of the PI3K-AKT pathway is inhibited, which makes the downstream apoptosis pathway activated, playing an important role in the treatment of breast cancer with kaempferol. Figure 11 . Figure 11Kaempferol inhibits the activation of PI3K-AKT pathway in MDA-MB-231 cells. *p<0.05, **p<0.01, ***p<0.001.
[0117] 3. Hoest33342 / Mito-Tracker Red CMXRos counterstaining to detect changes in cell nucleus and mitochondrial membrane potential
[0118] MDA-MB-231 cells in the logarithmic growth phase were seeded in a confocal dish at a concentration of 2*10 5 / ml. After 24 hours of drug treatment, add Mito-Tracker Red CMXRos working solution (1:8000). After incubation at 37℃ for 20 minutes, discard the Mito-Tracker Red CMXRos working solution, wash 3 times with PBS (10min / time), and add Hoechest33342 (1:2500) for counterstaining. After washing 3 times with PBS, add serum-free cell culture medium, and then observe using a laser confocal microscope.
[0119] In the scratch test of MDA-MB-231 treated with kaempferol, at 0h, the scratches of cells in each group were basically the same. At 12h, compared with the blank group, the kaempferol group could significantly reduce the migration rate of MDA-MB-231 cells, and it was statistically significant (p<0.05). However, at 24h of treatment, the scratch migration rate of MDA-MB-231 cells in each treatment group was higher than that in the blank group. Therefore, it is believed that kaempferol has a significant ability to inhibit migration in the short term of administration, but it does not inhibit the migration of MDA-MB-231 in the long term. See Figure 12 .in, Figure 12 Shows the effect of kaempferol on the migration ability of MDA-MB-231 cells, magnification 40x, *p<0.05, **p<0.01.
[0120] 4. DFCH-DA staining method to detect the level of intracellular reactive oxygen species
[0121] The intracellular ROS level in MDA-MB-231 cells was detected using a reactive oxygen species analysis kit (S0033, Beyotime). DCFH-DA was diluted 1:5000 with serum-free medium to a final concentration of 2 μmol / L. Cells in the logarithmic growth phase were selected to prepare a single cell suspension at a concentration of 2*10 5 / ml, add 500μl cell suspension to the confocal dish, and add 2ml complete culture medium after the cells adhere to the wall for three hours. After incubation for 12h, discard the culture medium, add 2ml of the corresponding drug solution, discard the old culture medium after 12h, incubate in the culture medium containing DCFH-DA for 20min, and then add 2ml PBS to wash 3 times. The image uses a laser confocal microscope to detect the ROS level in the cells at an excitation wavelength of 488nm and an emission wavelength of 525.
[0122] 5. Cell scratch assay to detect the effect of drugs on cell migration
[0123] Use a marker pen to draw five parallel lines on the back of the 6-well plate along the ruler. Prepare MDA-MB-231 single cell suspension at a concentration of 10 6 / ml. Add 1ml of cell suspension to the six-well plate and incubate in the incubator for 12h. When the cell confluence is about 100%, carefully discard the old culture medium and use a 200μl pipette tip to make a scratch along 5 parallel lines on the back of the vertical 6-well plate to form 5 intersections. Add PBS to the six-well plate and wash it carefully 3 times to wash off the cells that fell off during the scratching. The blank group, 10μmol / L cisplatin group, 50mg / L kaempferol group and 100mg / L kaempferol group were added to the six-well plate, and 2ml was added to each well. The 6-well plate with drug continued to be cultured in the incubator, and the 6-well plate was taken out at 0h, 12h, and 24h, and the bright field of an inverted microscope was used to record the position, with the 5 intersections as the baseline.
[0124] In the scratch test of MDA-MB-231 treated with kaempferol, at 0h, the scratches of cells in each group were basically the same. At 12h, compared with the blank group, the kaempferol group could significantly reduce the migration rate of MDA-MB-231 cells, and it was statistically significant (p<0.05). However, at 24h of treatment, the scratch migration rate of MDA-MB-231 cells in each treatment group was higher than that in the blank group. Therefore, it is believed that kaempferol has a significant ability to inhibit migration in the short term of administration, but it does not inhibit the migration of MDA-MB-231 in the long term. Figure 12 .
[0125] 6. Construction of a nude mouse breast cancer orthotopic tumor model
[0126] Thirty balb / c mice were randomly divided into five groups according to the random number table method, namely: blank group, control group, cisplatin group, kaempferol group, and kaempferol combined with cisplatin group, with 6 mice in each group. The subcutaneous inoculation method was used to prepare a breast in situ tumor mouse model: 4T1 mouse breast cancer cells cultured in 1640 medium were prepared as 1*10 7 / ml cell suspension. Except for the blank group, the other four groups of mice were inoculated with the above cell suspension into the fourth pair of mammary glands on the right side of balb / c mice, with an inoculation volume of 150μL / mouse. Seven days after inoculation, the mouse breast cancer orthotopic tumor model was successfully established. After 10 days of drug administration (100mg / kg / d of kaempferol by oral gavage and 2mg / kg / 2d of cisplatin by intraperitoneal injection), the animals were killed by cervical dislocation, and the tumors were removed and weighed.
[0127] In order to verify the anti-tumor effect of kaempferol on breast cancer cells in vivo, an orthotopic transplant tumor model of 4T1 breast cancer balb / c mice was established. After 7 days of inoculation, the tumor volume exceeded 100mm 3 , the mice were randomly divided into a blank group, a control group, a cisplatin group, a kaempferol group, and a kaempferol combined with cisplatin group, with 6 mice in each group. Compared with the control group, the tumor volume in the kaempferol group was significantly larger than that in the control group, and the volume in the kaempferol combined with cisplatin group was the smallest. The weight of mice in the cisplatin group was significantly lower than that in other groups. After 10 days of continuous administration, the mice were killed by cervical dislocation, and the tumor tissue was quickly peeled off and the volume and weight were measured. The results showed that the combined drug group could significantly reduce the weight of the in situ tumor, and kaempferol could reduce the effect of cisplatin on the normal physiological activities of mice. Figure 13 , Kaempferol inhibits the proliferation of breast cancer cells in mice, *p<0.05.
[0128] A. Dosing schedule for mice, when tumor volume exceeds 150mm 3 , 10 days after continuous administration of kaempferol and alternate-day administration of cisplatin, samples were collected for subsequent experimental analysis.
[0129] B. Mouse weight monitoring during drug administration: This chart directly shows the weight changes of tumor-bearing mice every day, that is, the average weight of each group of mice during drug administration. This helps to more intuitively understand whether the physiological condition of mice is normal when kaempferol and cisplatin are administered.
[0130] Control: A control group is used to compare the animals to other treated groups. In this graph, the weight changes in the control group reflect the natural growth of the animals under standard experimental conditions.
[0131] Cisplatin group: It is a commonly used chemotherapy drug that may cause a series of side effects, including loss of appetite, nausea, vomiting, etc. These side effects may affect the weight of animals. The weight of the Cisplatin group decreased significantly compared with the control group, which may be due to the side effects of the drug causing the animals to eat less or change their metabolism.
[0132] Kaempferol group: It is a natural flavonoid compound with multiple biological activities, including antioxidant, anti-inflammatory, etc. The body weight of the Kaempferol group increased or remained stable compared with the control group, indicating that the compound had no negative impact on the weight of the animals.
[0133] Combination group: This group received both Cisplatin and Kaempferol treatment. Since the two compounds have different biological activities and potential effects, their combination produces a synergistic effect. The weight change in the combination group reflects the combined effect of the two compounds on the weight of the animals. The weight change in the combination group was between the Cisplatin group and the Kaempferol group, indicating that kaempferol has a small toxic side effect on the weight change of mice.
[0134] C. Tumor weight: This chart records the weight of the tumor in the mice at the end of the experiment. By comparing the tumor weights of the different treatment groups, the effect of kaempferol on the final tumor size can be evaluated. By comparing the tumor weights of each group, it can be found that Kaempferol has an inhibitory effect on tumor growth, while Cisplatin has a more significant inhibitory effect. At the same time, the combination of the two drugs (Combination group) produced the best inhibitory effect, indicating that there is a synergistic effect between them.
[0135] Figures D and E are tumor volume and weight graphs. This graph shows the changes in tumor volume and weight of mice in different treatment groups. The tumor volume of the Combination group (green) was the smallest and grew the slowest, which fully demonstrated that the combination treatment of Cisplatin and Kaempferol had a very significant effect in inhibiting tumor growth. The inhibition rates of kaempferol and cisplatin alone were 15% and 10%, respectively, which were much lower than the 67% inhibition rate of the combination group. This combination treatment not only exceeded the control group that did not receive any treatment, but also far exceeded the effect of using any one drug alone.
[0136] 7. HE staining to observe tissue
[0137] After the tumor tissue was collected, paraffin tissue sections of breast tumor were prepared and stained with hematoxylin-eosin (HE) staining solution.
[0138] The removed tumor was stained with H&E and visible under an optical microscope (200×). In the H&E staining of breast tumors, normal breast cells showed purple nuclei and light pink cytoplasm. Breast tumor cells are characterized by abnormally low nuclear-cytoplasmic ratio, morphological deformities and increased cell density. In the chemotherapy drug cisplatin group, the mouse mammary tissue was arranged in a disordered manner, the glandular structure disappeared, and the atypia was obvious. Under the treatment of kaempferol, the mammary tissue was arranged tightly and disorderly, with large and darkly stained nuclei. Under the treatment of kaempferol combined with cisplatin, the breast tumor tissue of mice was significantly destroyed, and had the characteristics of both the kaempferol group and the cisplatin group.
[0139] 8. Immunohistochemistry to detect protein expression in vivo
[0140] The PV-6000 method was used to detect changes in AKT and Bcl2 protein expression in tissues. Tumor specimens were fixed with 5% formaldehyde solution, embedded in paraffin, sliced at 4 μm, dewaxed and hydrated. The sections were immersed in anti-3% H2O2 solution, and then high-pressure heat repair antigens were performed. Primary antibody was added and incubated overnight at 4°C. After rinsing with PBS, goat anti-mouse IgG secondary antibody was added and incubated at room temperature for 30 minutes. DAB color development was performed for 5 minutes, and ultrapure water was used to terminate the color development, and 1% hydrochloric acid alcohol was added for differentiation for 3 seconds. After gradient alcohol dehydration, neutral resin was added to the dried sections and sealed, and photographed and recorded under an upright microscope.
[0141] Kaempferol affects the expression level of breast tumor-related proteins in vivo: The removed mouse orthotopic transplanted tumor was subjected to immunohistochemical staining. The results showed that the expression levels of apoptosis-related antigens AKT and Bcl2 in the drug-treated group were inhibited, and the results were statistically significant (p<0.0001). This shows that kaempferol inhibits the activation of the PI3K-AKT pathway in vivo and mediates the occurrence of downstream apoptosis, thereby achieving the effect of treating breast cancer. The difference is statistically significant, see Figure 16 , Kaempferol inhibited the expression of AKT and Bcl2 in vivo, ****p<0.0001.
[0142] It should be noted that the above specific embodiments only exemplify several possible application modes of the present invention, which are intended to illustrate the principles of the invention and do not limit the embodiments of the present invention. Any changes, improvements or substitutions guided by the spirit and principles of the present invention shall be regarded as the protection content of the present invention.
Claims
1. A pharmaceutical composition for regulating the PI3K-AKT signaling pathway of breast cancer cells, characterized in that: The composition comprises kaempferol as a main active ingredient.
2. The pharmaceutical composition according to claim 1, characterized in that: At least one pharmaceutically acceptable carrier or adjuvant is also included.
3. The pharmaceutical composition according to claim 1, characterized in that: The composition is used for inhibiting breast cancer cell proliferation and inducing cell apoptosis by affecting the expression of PI3K, AKT, BAD and BCL-2 genes.
4. The pharmaceutical composition according to claim 1, characterized in that: Contains liquorice extract as a co-active ingredient.
5. The pharmaceutical composition according to claim 1, characterized in that: The composition comprises kaempferol and cisplatin as active ingredients.
6. The pharmaceutical composition according to claim 1, characterized in that: When used as a pharmaceutical composition for mammals, the ratio of kaempferol to cisplatin is (5-80):1; wherein kaempferol is 0.71-40 mg / kg / d and cisplatin is 0.036-2 mg / kg / d.
7. The pharmaceutical composition according to claim 6, characterized in that: In the case of a pharmaceutical composition for mice, the ratio of kaempferol to cisplatin is (5-80):1; wherein kaempferol is 10-40 mg / kg / d; cisplatin is 0.5-2 mg / kg / d.
8. The pharmaceutical composition according to claim 6, characterized in that: In the case of a pharmaceutical composition for human use, the ratio of kaempferol to cisplatin is (5-79):1; wherein the kaempferol is 0.71-2.85 mg / kg / d, and the cisplatin is 0.036-0.14 mg / kg / d.
9. The pharmaceutical composition according to claim 1, characterized in that: The composition is in the form of an oral preparation, an injection, a sustained-release preparation or a targeted delivery system.
10. A pharmaceutical use using the composition according to claim 1, characterized in that: The use relates to the preparation of a drug for inhibiting the proliferation or metastasis of mammalian breast cancer cells.
